{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:38:21Z","timestamp":1784547501965,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01767-1","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T10:01:36Z","timestamp":1779012096000},"page":"3275-3283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03826901","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaDe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Maslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K. R.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise","family":"\u00d8sterdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f8hoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Elenius","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"issue":"5","key":"1767_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermat. 2022;86(5):357\u201378.","journal-title":"Contact Dermat"},{"key":"1767_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332.","journal-title":"Ther Clin Risk Manag"},{"key":"1767_CR3","unstructured":"LEO Pharma A\/S. ANZUPGO. Summary of product characteristics. 2024.  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf. Accessed 21 April 2025."},{"key":"1767_CR4","unstructured":"LEO Pharma Inc. ANZUPGO. Highlights of prescribing information. 2025.https:\/\/www.leo-pharma.us\/AnzupgoPI. Accessed 8 Aug 2025."},{"issue":"1","key":"1767_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41\u201351.","journal-title":"Inflamm Res"},{"key":"1767_CR6","unstructured":"LEO Pharma Inc. Product monograph. Including patient medication information. ANZUPGO.  2025. https:\/\/pdf.hres.ca\/dpd_pm\/00081515.PDF. Accessed 17 Oct 2025."},{"issue":"10451","key":"1767_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet"},{"issue":"10490","key":"1767_CR8","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gimenez-Arnau","year":"2025","unstructured":"Gimenez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Lancet. 2025;405(10490):1676\u201388.","journal-title":"Lancet"},{"issue":"4","key":"1767_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"key":"1767_CR10","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of allergy, asthma and immunology\/American college of allergy, asthma and immunology joint task force on practice parameters GRADE- and institute of medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312."},{"key":"1767_CR11","unstructured":"Incyte Corporation. OPZELURA. Highlights of prescribing information.  2022. https:\/\/www.opzelura.com\/opzelura-prescribing-information. Accessed 3 July 2025."},{"key":"1767_CR12","unstructured":"AbbVie Inc. RINVOQ. Highlights of prescribing information. 2019.  https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 11 Aug 2025."},{"key":"1767_CR13","unstructured":"Pfizer Inc. CIBINQO.  Highlights of prescribing information. 2022. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16652. Accessed 11 Aug 2025."},{"key":"1767_CR14","unstructured":"Bunick C, Schlapbach C, Erhan U, et al. Delgocitinib cream formulation development for chronic hand eczema (CHE): insights from patient preference and skin penetration studies. Presented at: European Academy of Dermatology and Venereology (EADV) Spring Symposium, 22\u201324 May 2025; Prague, Czech Republic."},{"key":"1767_CR15","doi-asserted-by":"publisher","unstructured":"Thaci D, Gooderham M, Lovato P, Madsen DE, Soehoel A, Bissonnette R. Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe chronic hand eczema. J Eur Acad Dermatol Venereol. 2025;39(9):1612\u201321. https:\/\/doi.org\/10.1111\/jdv.20777.","DOI":"10.1111\/jdv.20777"},{"issue":"2","key":"1767_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/09546634.2020.1789050","volume":"33","author":"SG Danby","year":"2022","unstructured":"Danby SG, Draelos ZD, Gold LFS, et al. Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermatolog Treat. 2022;33(2):685\u201398.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1767_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2310\/6620.2008.07054","volume":"19","author":"J Coloe","year":"2008","unstructured":"Coloe J, Zirwas MJ. Allergens in corticosteroid vehicles. Dermatitis. 2008;19(1):38\u201342.","journal-title":"Dermatitis"},{"issue":"16","key":"1767_CR18","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1021\/acs.jpcb.3c06784","volume":"128","author":"J Mistry","year":"2024","unstructured":"Mistry J, Notman R. Mechanisms of the drug penetration enhancer propylene glycol interacting with skin lipid membranes. J Phys Chem B. 2024;128(16):3885\u201397.","journal-title":"J Phys Chem B"},{"issue":"2","key":"1767_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/idoj.idoj_648_24","volume":"16","author":"V Patel","year":"2025","unstructured":"Patel V, Gaurav V. Role of polyethylene glycol in dermatology. Indian Dermatol Online J. 2025;16(2):227\u201334.","journal-title":"Indian Dermatol Online J"},{"issue":"1-2","key":"1767_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijpharm.2013.04.083","volume":"452","author":"ML Reid","year":"2013","unstructured":"Reid ML, Benaouda F, Khengar R, Jones SA, Brown MB. Topical corticosteroid delivery into human skin using hydrofluoroalkane metered dose aerosol sprays. Int J Pharm. 2013;452(1\u20132):157\u201365.","journal-title":"Int J Pharm"},{"key":"1767_CR21","doi-asserted-by":"publisher","unstructured":"Zhang Y, Lane ME, Moore DJ. An investigation of the influence of PEG 400 and PEG-6-Caprylic\/Capric glycerides on dermal delivery of niacinamide. Polymers. 2020;12(12):290. https:\/\/doi.org\/10.3390\/polym12122907.","DOI":"10.3390\/polym12122907"},{"key":"1767_CR22","doi-asserted-by":"publisher","unstructured":"Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol. 2025;93:95\u2013103. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.008.","DOI":"10.1016\/j.jaad.2025.03.008"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01767-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:25:03Z","timestamp":1781753103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01767-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1767"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01767-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melinda Gooderham has been an investigator, speaker, and\/or advisor for: AbbVie, Amgen, Akros, AnaptysBio, Apogee, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma A\/S, MedImmune, Merck, Meiji, Moonlake, Novartis, Oruka, Pfizer, Q32 Bio, Reistone, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne. Christopher G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Takeda, Timber, and Palvella; a consultant for AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Dermavant, Eli Lilly, EPI Health\/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Teladoc, Triveni, and UCB. Christopher G. Bunick is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. JiaDe Yu has served as a consultant\/advisory board\/investigator for the following: Abbvie, Arcutis, Astria, Dermavant, iRhythm, LEO Pharma A\/S, Lilly, National Eczema Association, O\u2019Glacee, Pfizer, Sanofi, Smartpractice, Sol\u2013Gel; and also receives honorarium from UptoDate. Douglas Maslin, Marie Louise \u00d8sterdal, Anders S\u00f8hoel, and Daniel Elenius Madsen are employees of LEO Pharma A\/S. Shannon K.R. Schneider is an employee of LEO Pharma Inc. Lawrence F. Eichenfield has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma A\/S, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Takeda, Target RWE, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Trial protocols were approved by all relevant ethics committees and institutional review boards (DELTA 2, see [\n                      \n                      ]; phase 1 AD trial, see Electronic Supplementary Material Table\n                      \n                      ). The trials were conducted according to the principles of the Declaration of Helsinki and the International Council on Harmonization Guidelines for Good Clinical Practice and conformed with all relevant country-specific laws and regulations. All patients, or their legal representatives, provided written informed consent. In DELTA 2, patients at selected trial sites had the additional option to participate in a photography component to capture disease status over time; participating patients were required to provide additional informed consent, including consent for their photographs to be published for scientific and\/or commercial purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}